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Since  2005,  the Government  of  the  United  States  of  America  has  provided  more  than  US$  50 million
to  advance  inﬂuenza  vaccine  development  in  low-resourced  countries.  This  programme  has  provided  a
unique  opportunity  for the  US  Government  to  develop  a comprehensive  view  of,  and  to understand  bet-
ter  the  challenges  and  future  needs  for inﬂuenza  vaccines  in  the  developing  world.  The  funding  for  this
programme  has  been  primarily  through  a cooperative  agreement  with  the  World  Health  Organization
(WHO)  to  support  directly  its  capacity-building  grants  to government-owned  or  -supported  vaccine  man-
ufacturers  in  developing  countries.  A  second  cooperative  agreement  with  the  Program  for  Appropriate
Technologies  in  Health  (PATH)  was  initiated  to  accelerate  the  completion  of  a  current  Good  Manufactur-
ing  Practice  cGMP  production  facility,  along  with  supporting  facilities  to  obtain  a reliable  source  of  eggs,
and  to  conduct  clinical  trials  of  inﬂuenza  vaccine  manufactured  in  Vietnam.  This  mechanism  of  utilizing
cooperative  agreements  to  support  capacity-building  for vaccine  development  in  low-resourced  settings
has  been  novel  and  unique  and  has  yielded  fruitful  returns  on  minimal  investment.
The  information  derived  from  this  programme  helps  to clarify  not  only  the  development  challenges
for  inﬂuenza  vaccines  and  how  the  United  States  may  assist  in  meeting  those  challenges,  but  also  other
vaccine  development  issues  common  to manufacturers  in developing  countries.  While  building  the  ini-
tial  capacity  to produce  inﬂuenza  vaccines  can  be a  straightforward  exercise,  the  sustainability  of  the
enterprise  and  expansion  of  subsequent  markets  will  be the  key  to future  usefulness.  There  is  hope  for
expansion  of  the  global  inﬂuenza  vaccine  market.  Ongoing  burden  of  disease  studies  are  elucidating  the
impact  of  inﬂuenza  infections,  particularly  in  children,  and  more  countries  will  take  note  and  respond
accordingly,  since  respiratory  diseases  are  now  the  number  one  killer  of children  under  ﬁve  years  of age.
In  addition  to  achievements  described  in this  issue  of  Vaccine,  the  programme  has  been successful
from  the  US  perspective  because  the  working  relationships  established  between  the  US  Department
of  Health  and  Human  Services’  (HHS)  Assistant  Secretary  for  Preparedness  and  Response  Biomedical
Advanced  Research  and  Development  Authority  (BARDA)  and  its partners  have  assisted  in  advancing
inﬂuenza  vaccine  development  at  many  different  levels.  A  few  examples  of BARDA’s  support  include:
establishment  of egg-based  inﬂuenza  vaccine  production  from  “scratch”,  enhancement  of live  attenuated
inﬂuenza  vaccine  (LAIV)  production  techniques  and  infrastructure,  completion  of ﬁll/ﬁnish  operations
for  imported  bulk  vaccine,  and  training  in  advanced  bio-manufacturing  techniques.
These  HHS-supported  programmes  have  been  well-received  internationally,  and  we  and our  partners
hope  the  successes  will  stimulate  even  more  interest  within  the  international  community  in maximizing
or  inﬂglobal  production  levels  f
. Background to US funding for international inﬂuenza
accine capacity buildingDue  to the increasing number of human deaths since 2004 dur-
ng the regional expansion in Asia of the H5N1 inﬂuenza strain, con-
ern was high that this virus would become transmissible between
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humans. Indeed, many articles by prominent scientists and pub-
lic health ofﬁcials warned that this virus could cause a devastating
pandemic resulting in high mortality. In response, the United States
published the National Strategy for Pandemic Inﬂuenza [1], fol-
lowed by an HHS implementation plan [2], both of which stated a
clear commitment to supporting international pandemic prepared-
ness. Diseases do not respect national borders so increasing the
Open access under CC BY-NC-ND license.capacity to make and use inﬂuenza vaccines in more countries can
help every country reduce the spread of the inﬂuenza virus.
The  US government included a commitment in its strategy to
implement the World Health Assembly resolution WHA58.5 which
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peciﬁcally called for increased inﬂuenza vaccine manufacturing
apacity in developing countries.
In Vietnam, in particular, concern was high that the close con-
ection between backyard poultry kept by a large percentage of
he population and limited rural medical infrastructure would pro-
uce ideal conditions for development of a “bird ﬂu” pandemic.
hus, initial efforts at vaccine capacity-building took the form of an
HS grant to the state-owned company in Hanoi, VABIOTECH, to
nhance its capacity to produce inﬂuenza vaccine produced under
urrent Good Manufacturing Practice (cGMP). Further international
upport followed as a component of legislation that appropriated
unding through the Public Health and Social Services Emergency
und [3]. This funding has been made available on a regular basis
rom 2005 to 2011. Such capacity building activities were noted
ecently as one of seven prioritized to support global pandemic
reparedness [4].
.  WHO  cooperative agreement 2006 to date
BARDA realized that support and maintenance of bilateral coop-
rative agreements with developing countries and their varying
elationships would require a level of personnel beyond its capac-
ty. Given that WHO  was speciﬁcally coordinating an initiative
o support inﬂuenza vaccine capacity-building as a component
f the 2006 The Global Action Plan (GAP) to increase supply
f pandemic inﬂuenza vaccines (http://www.who.int/vaccines-
ocuments/DocsPDF06/863.pdf),  it was decided by HHS that
upport to the WHO-managed initiative was the most effective
tilization of US funds for this purpose. Thus, US funding of US$
0 million helped to initiate the WHO  grant programme described
n this Journal issue. Three subsequent cooperative agreements
ith WHO  (2008, 2009 and 2010 to the present) have assisted in
ontinued and expanded support of vaccine manufacturers in ten
ountries: Brazil, Egypt, India, Indonesia, Mexico, Romania, Russia,
erbia, Thailand and Vietnam.
.  PATH cooperative agreement 2009 to date
In 2009, BARDA used its international capacity-building funds
o establish a US$ 7.9 million cooperative agreement with PATH,1
hich allowed the support of ﬁnal developmental processes for an
gg-grown inﬂuenza vaccine at one of the original WHO  awardees,
he Institute of Vaccines and Medical Biologicals (IVAC) in Vietnam.
he PATH supported phase 1 clinical trials from vaccine produced
t IVAC are expected to be initiated by 2012. The close working rela-
ionship between BARDA, PATH and WHO, as well as the Vietnam
inistry of Health, has helped to assure that this project will be
uccessful, and the egg-based production facility, partially funded
hrough these collaborations, will be able to produce millions of
oses per year of pandemic vaccine.
. H1N1 pandemic inﬂuence
While  experts world-wide recognized the potential for an out-
reak of pandemic inﬂuenza to occur at any time and many
ountries had begun preparing for such events, much more was
eeded to be fully prepared when H1N1 emerged. Nevertheless,
1N1 had some positive effects on the progress of WHO  grantee
rogrammes. In several countries, it served to heighten aware-
ess and interest at the government level to move from focusing
olely on building inﬂuenza vaccine capacity to encouraging larger
cale production and stimulating new markets. This is important
1 http://www.path.org/projects/pandemic ﬂu partners.php.ne 29S (2011) A48– A50 A49
to ensure sustainable production and use of the vaccine. The best
evidence for this is in India where the Serum Institute of India,
supported by the HHS/WHO funding, has developed, licensed and
distributed over 5 million doses of its H1N1 LAIV.
Technology and intellectual property transfer activities medi-
ated by WHO  have resulted in expanded LAIV production in both
India and Thailand using vaccines based upon the LAIV backbone
developed by the Institute of Experimental Medicine in Russia. Cou-
pled with the ground-work established by WHO, high-performing
partners, and local government support, this vaccine was ready in
unprecedented time.
5.  New initiatives
BARDA is now considering the next phases of this impor-
tant international capacity-building effort. In addition to seeing
through the milestones in the WHO  cooperative agreements
grantees, BARDA is committed to supporting new initiatives for
2010–2011 laid out in the WHO  programme and cooperative
agreement as well as US-based training for personnel from the
WHO/HHS funded sites. This initiative would support developing
country manufacturers in advanced manufacturing techniques and
will be made available through cooperative agreements between
HHS and Utah State University and North Carolina State University.
Classes begin at these cutting-edge vaccine manufacturing training
facilities in February 2011.
Another  initiative for 2011 is to provide support for the devel-
opment of adjuvants that are free of intellectual property barriers,
available and produced by WHO/HHS grantees for evaluation with
their vaccines. Cooperative agreements with the University of Lau-
sanne in Switzerland and the Infectious Disease Research Institute
in Seattle, USA have been initiated to implement this programme
(see article by the Vaccine Formulation Laboratory in this issue).
Other  HHS support to continue building capacity for interna-
tional inﬂuenza vaccine manufacturing in 2011 and beyond is
under discussion. Options being considered include more support
for LAIV use in developing countries. Other options are feasibility
and pilot studies for “modular, multi-product vaccine manufac-
turing facilities” in certain regions to support the production of
seasonal vaccines that could be quickly switched to full-scale
pandemic inﬂuenza vaccine production in a crisis. Such a facility
would allow the co-existence of egg- and cell- or recombinant-
based technologies, enabling a small, regional facility to follow
the evolution of technology and circumvent the old paradigm of a
single facility for a single vaccine.
It is important, of course, to assure that appropriate metrics to
measure and monitor the success of the various programmes are
in place. Clearly, tangible success thus far has been outlined in this
issue. However, many intangible, not-so-obvious beneﬁts related
to this international support are also important. For example, sup-
port for the WHO  programme has stimulated further government
interest in inﬂuenza vaccine development, as witnessed by sev-
eral high proﬁle commitments of funding in India, Indonesia and
Thailand. International diplomacy, virus and sample sharing, and
early diagnostic and surveillance beneﬁts are other such beneﬁts.
The success of these programmes and lessons learned will help to
provide the foundation for the global community to seriously con-
template, and take further steps to develop sustainable inﬂuenza
vaccine markets where previously there were none.
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